Prometheus Biosciences, Inc. Common Stock
RXDX
RXDX was delisted on the 15th of June, 2023.
144 hedge funds and large institutions have $1.94B invested in Prometheus Biosciences, Inc. Common Stock in 2022 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 51 increasing their positions, 30 reducing their positions, and 18 closing their positions.
156% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 18
123% more capital invested
Capital invested by funds: $870M → $1.94B (+$1.07B)
100% more funds holding in top 10
Funds holding in top 10: 5 → 10 (+5)
70% more repeat investments, than reductions
Existing positions increased: 51 | Existing positions reduced: 30
24% more funds holding
Funds holding: 116 → 144 (+28)
1.73% more ownership
Funds ownership: 78.59% → 80.33% (+1.7%)
6% less call options, than puts
Call options by funds: $38.7M | Put options by funds: $41.4M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$53.3M |
| 2 |
State Street
Boston,
Massachusetts
|
+$50.4M |
| 3 |
FAM
Fred Alger Management
New York
|
+$36.3M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$15M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$14.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$41.8M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$35.4M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$29.6M |
| 4 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$25.8M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$13.8M |
RXDX Hedge Fund Activity: Q3 2022 in Review
144 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in Prometheus Biosciences, Inc. Common Stock (RXDX) for Q3 2022, worth a combined $1.94B — up 123% from $870M a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new RXDX positions and 18 closed out — a net gain of 28 holders — while 51 added to existing stakes and 30 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $53.3M. The largest seller was Woodline Partners, cutting an estimated $41.8M.
- 144 institutional investors held Prometheus Biosciences, Inc. Common Stock (RXDX) as of Q3 2022, up from 116 in Q2 2022.
- Funds reported $1.94B of Prometheus Biosciences, Inc. Common Stock stock for Q3 2022, up 123% quarter-over-quarter.
- 46 funds opened new Prometheus Biosciences, Inc. Common Stock positions in Q3 2022 and 18 closed out, a net change of +28 holders.
- The largest Prometheus Biosciences, Inc. Common Stock buyer in Q3 2022 was Adage Capital Partners, an estimated $53.3M added.
- The largest Prometheus Biosciences, Inc. Common Stock seller in Q3 2022 was Woodline Partners, an estimated $41.8M sold.
Based on aggregated 13F filings for Q3 2022.